aTyr Pharma ATYR 深 沪
等待开盘 11-14 09:30:00 美东时间
6.105
-0.105
-1.69%
华盛通- 最 高6.535
- 今 开6.24
- 成交量 3.80万股
- 最 低 5.9569
- 昨 收 6.21
- 总市值 1556.30万
- 52周最高 44.40
- 市盈率 静 --
- 换手率 1.49%
- 52周最低 4.068
- 委 比 95.99%
- 总股本 254.92万
- 历史最高 15842.40
- 量 比 0.42
- 振 幅 9.31%
- 历史最低 4.068
- 每 手 1
- 风险率 9.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, a clinical-stage biotech company, announced its participation in two upcoming investor conferences in November and December 2026. The first conference, the Jefferies Global Healthcare Conference in London, will take place on November 17-18, featuring 1x1 investor meetings. The second conference, Piper Sandler's 38th Annual Healthcare Conference in New York, will occur on December 3, with a Fireside Chat led by CEO Sanjay S. Shukla, M...
11-11 13:00
美股大行评级 | 巴克莱维百济神州"超配"评级！目标价从415美元上调至446美元
今日重点评级关注：瑞银：维持Liberty Media"中性"评级，目标价从110美元升至1116美元；杰富瑞：维持伊诺维奥制药"买入"评级，目标价从3美元升至8美元
11-09 14:00
aTyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
On November 6, 2026, aTyr Pharma, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") related to the sale of the Company’s common stock, par value $0.001 per share (the "Common Stock") with the Securities and Exchange Commission (the "SEC") pursuant to which the Company ...
11-07 05:14
Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4
Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Equal-Weight and raises the price target from $1 to $4.
11-06 22:38
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma announced the publication of Phase 3 EFZO-FIT™ study results for efzofitimod in pulmonary sarcoidosis patients in *The Lancet Respiratory Medicine*. The study involved 268 patients and focused on reducing steroid use and improving patient-reported outcomes (PROs). While efzofitimod did not achieve a statistically significant steroid reduction compared to placebo, it improved multiple PRO measures, including fatigue and lung function s...
10-29 12:00
aTyr Pharma Announces 1-For-40 Reverse Stock Split, Effective Oct. 28
aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will effect a reverse stock split of its issued and outstandi...
10-27 21:02
aTyr Pharma Announces One-for-40 Reverse Stock Split
aTyr Pharma announced a 1-for-40 reverse stock split effective October 28, 2026, to comply with Nasdaq's minimum bid price requirement. The stock will begin trading on a split-adjusted basis on October 29, 2026, under the symbol "ATYR" with a new CUSIP number. The reverse split will reduce outstanding shares from ~100.5 million to ~2.5 million, proportionally adjusting stock options, warrants, and restricted stock units. Fractional shares will be...
10-27 13:00
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma与Albert Einstein医学院合作开发抗NRP2抗体ATYR2810用于治疗儿童骨肉瘤。该抗体通过阻断NRP2信号通路，抑制免疫抑制，已在多种癌症模型中显示抗肿瘤效果。合作由骨肿瘤专家Bang H. Hoang博士领导，旨在探索NRP2在骨肉瘤中的作用，为这种侵袭性癌症提供新治疗策略。
10-19 11:00
aTyr Pharma Shareholders Approve Potential Reverse Stock Split
aTyr Pharma ( ($ATYR) ) has issued an update. At the October 16, 2026 Special M...
10-17 04:36
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic in 2027. SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ...
10-13 20:04
